Gilead Sciences' (GILD) stock is getting killed this morning and for good reason. After making an $11 billion acquisition of biotech Pharmasset to become a dominant hepatitis C drug developer, Gilead said six out of eight patients given an …
Gilead Sciences reported Tuesday that sales of its Hepatitis C drug, Sovaldi, fell nearly 20 percent from the prior quarter. The stock dropped nearly 3 percent in after-hours trading. Gilead also announced its third quarter earnings, posting …
Still flush from the unprecedented debut of its blockbuster hepatitis C drug, Gilead Sciences watched its stock continue to rise Wednesday, even as a top payer remained opposed to Sovaldi's price. Shares of the Foster City company, which …
Shares of Gilead and Vertex jumped Tuesday after a Bernstein analyst said Gilead should “pull the trigger” on a deal with Vertex.
Gilead Sciences (ticker: GILD) shareholders have endured a steady downward drift since the stock peaked at its all-time high of $119.59 back in mid-2015. On Friday, Barclays analyst Geoff Meacham released a new research note in which …
Gilead Sciences has been a dream stock for long-term investors. Anyone who was smart enough to get in at the IPO in 1992 and hold the stock until today are sitting on a gain of around 17,000%! That kind of performance is simply …
Research-based biopharmaceutical juggernaut, Gilead Sciences (GILD) announced its financial results for fiscal Q3 2014 after the market closed on Tuesday. The company’s total revenues for the third fiscal quarter of 2014 rose to $6.04 …
10 stocks we like better than Gilead Sciences When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the …
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here. Gilead Sciences (NASDAQ: GILD) declared a quarterly